KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Gains from Investment Securities (2016 - 2026)

Ionis Pharmaceuticals (IONS) has disclosed Gains from Investment Securities for 17 consecutive years, with -$8000.0 as the latest value for Q1 2026.

  • For Q1 2026, Gains from Investment Securities rose 98.0% year-over-year to -$8000.0; the TTM value through Mar 2026 reached $9.7 million, up 392.65%, while the annual FY2024 figure was $14.7 million, 4.44% up from the prior year.
  • Gains from Investment Securities hit -$8000.0 in Q1 2026 for Ionis Pharmaceuticals, up from -$77.7 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $107.4 million in Q3 2025 and bottomed at -$77.7 million in Q4 2025.
  • Average Gains from Investment Securities over 5 years is $1.2 million, with a median of $9000.0 recorded in 2022.
  • Year-over-year, Gains from Investment Securities surged 9122.22% in 2023 and then tumbled 154292.31% in 2025.
  • Ionis Pharmaceuticals' Gains from Investment Securities stood at $4.4 million in 2022, then tumbled by 67.17% to $1.4 million in 2023, then plummeted by 447.38% to -$5.0 million in 2024, then plummeted by 1464.44% to -$77.7 million in 2025, then soared by 99.99% to -$8000.0 in 2026.
  • According to Business Quant data, Gains from Investment Securities over the past three periods came in at -$8000.0, -$77.7 million, and $107.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.